MARK4 Antibody (C-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP7145b
Background:
MARK4 contains an N-terminal serine/threonine kinase domain, a central ubiquitin-associated domain, and a C-terminal KA1-associated kinase domain. RT-PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells. Northern blot analysis reveals ubiquitous expression of a 3.6-kb transcript, with highest expression in testis. Immunofluorescence microscopy demonstrates homogeneous cytoplasmic expression. Colony-forming assays show that MARK4 antisense reduces the growth of SNU475 cells. It has been suggested that MARK4 provides a growth advantage to cells.
Other Names:
MAP/microtubule affinity-regulating kinase 4, MAP/microtubule affinity-regulating kinase-like 1, MARK4, KIAA1860, MARKL1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7145b was selected from the C-term region of human MARK4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: MARK4 {ECO:0000303|PubMed:14594945, ECO:0000312|HGNC:HGNC:13538}
Gene ID: 57787
Primary Accession: Q96L34
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
MARK4 contains an N-terminal serine/threonine kinase domain, a central ubiquitin-associated domain, and a C-terminal KA1-associated kinase domain. RT-PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells. Northern blot analysis reveals ubiquitous expression of a 3.6-kb transcript, with highest expression in testis. Immunofluorescence microscopy demonstrates homogeneous cytoplasmic expression. Colony-forming assays show that MARK4 antisense reduces the growth of SNU475 cells. It has been suggested that MARK4 provides a growth advantage to cells.
Other Names:
MAP/microtubule affinity-regulating kinase 4, MAP/microtubule affinity-regulating kinase-like 1, MARK4, KIAA1860, MARKL1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7145b was selected from the C-term region of human MARK4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: MARK4 {ECO:0000303|PubMed:14594945, ECO:0000312|HGNC:HGNC:13538}
Gene ID: 57787
Primary Accession: Q96L34
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review